Literature DB >> 15308595

Single-tube method for nucleic acid extraction, amplification, purification, and sequencing.

Rebecca L Margraf1, Sam Page, Maria Erali, Carl T Wittwer.   

Abstract

BACKGROUND: The hepatitis C virus (HCV) genotype determines patient prognosis and duration of treatment, but sequencing of the gene is lengthy and labor-intensive. We used a commercially available nucleic acid extraction system to develop a single-tube extraction-to-sequencing (STETS) method for HCV genotyping.
METHODS: HCV RNA was purified and amplified in tubes coated with a solid-phase matrix that irreversibly bound nucleic acid during the extraction step. After reverse transcription-PCR, the amplicon was adsorbed to the original extraction matrix for purification and use in the subsequent sequencing reactions.
RESULTS: The STETS method generated genotyping-quality sequence for a range of HCV titers from 500 to 6,000,000 IU/mL. If a viral sample was detected during real-time reverse transcription-PCR, it could be sequenced and genotyped. Read lengths >600 bases were observed with the STETS method. Mixed infections were detected and genotyped if at least 15% of the minor species was present. Combining the STETS method with consecutive sequencing provided a means of performing both forward and reverse sequencing in a single tube.
CONCLUSIONS: A single-tube nucleic acid extraction-to-sequencing method, which requires less time and labor than conventional methods, generates HCV sequence data that are equivalent to conventional methods and can be used to genotype HCV.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308595     DOI: 10.1373/clinchem.2004.035808

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  1 in total

1.  A single-tube nucleic acid extraction, amplification, and detection method using aluminum oxide.

Authors:  Shale Dames; L Kathryn Bromley; Mark Herrmann; Marc Elgort; Maria Erali; Roger Smith; Karl V Voelkerding
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.